PrimeRFP SCOUT · Federal Contract Recompete Brief

HHSO100201700012CMERCK - EBOLA ZAIRE vaccine UPDATE — Merck Sharp & Dohme Corp

Merck Sharp & Dohme Corp holds $7.7B across 101 federal awards, concentrated at Department of Health and Human Services (HHS). This PIID sits alongside 1 related award in the incumbent pipeline. Competition previously drew 2 offers. Set-aside status: NONE. Recompete timing centers on the Sep 27, 2027 PoP end — agencies typically plan 12–18 months ahead.

Barda - Aspr / Daappo / Barda Dcma

Awarding office

Merck Sharp & Dohme Corp

Recipient

Sep 27, 2027

PoP end

$33M

Obligated

541711

NAICS

6505

PSC

NONE

Set-aside

2 bidders on last award

Watch this recompete

One email. No account. We ping you if the window moves.

Score my position vs Merck Sharp & Dohme Corp — $90

Contract facts

NONE

Contract numberHHSO100201700012C

AgencyBarda - Aspr / Daappo / Barda Dcma

Awarding officeBarda - Aspr / Daappo / Barda Dcma

IncumbentMerck Sharp & Dohme Corp

UEIFCFDA78HKKG2

NAICS541711

No full NAICS 541711 intel page yet. Browse NAICS intelligence

PSC6505

Place of performanceWHITEHOUSE STATION, NJ

Related solicitation17100SOL00013

PoP end (current)Sep 27, 2027

Obligated$33M

MERCK - EBOLA ZAIRE VACCINE UPDATE SECTION J is a federal NONE award for Barda - Aspr / Daappo / Barda Dcma held by Merck Sharp & Dohme Corp. Estimated value $236.3M ($33M obligated). Current period of performance ends Sep 27, 2027. Last award drew 2 bidders. Place of performance: WHITEHOUSE STATION, NJ. Related solicitation 17100SOL00013.

MERCK - EBOLA ZAIRE VACCINE UPDATE SECTION J

Recompete timing

Public

● Expiring in 385 days

Current PoP ends Sep 27, 2027 (385 days remaining). Agencies typically plan 12–18 months ahead — position before the PoP clock runs out.

Incumbent footprint

Public record

Merck Sharp & Dohme Corp — $7.7B obligated across 101 awards (firm-wide, all agencies) · lead buyer Department of Health and Human Services (HHS).

% of firm-wide obligated ($7.7B) · all agencies

Department of Health and Human Services (HHS)$7.7B · 100%Department of Veterans Affairs (VA)$2.3M · 0%Department of Justice (DOJ)$98K · 0%

Open full company profile →

Related awards

Same incumbent

36C26026F0282

WINREVAIR 45MG/VIAL INJ,LYPHL

$342K

May 31, 2027

Query this award live in SCOUT via MCP — personalized scoring, watchlists, and capture workflow across the corpus. Learn about SCOUT MCP →

Frequently asked questions

What is contract HHSO100201700012C?

HHSO100201700012C (MERCK - EBOLA ZAIRE vaccine UPDATE) is a Barda - Aspr / Daappo / Barda Dcma award with an estimated value of $236.3M, currently held by Merck Sharp & Dohme Corp. Figures are USASpending-sourced public-record facts plus SCOUT recompete analysis.

Which office awarded HHSO100201700012C?

Barda - Aspr / Daappo / Barda Dcma awarded HHSO100201700012C to Merck Sharp & Dohme Corp.

Who is the incumbent on HHSO100201700012C?

Merck Sharp & Dohme Corp is the incumbent with $7.7B across 101 related awards in SCOUT’s public footprint. The current period of performance ends Sep 27, 2027.

When does Merck Sharp & Dohme Corp’s HHSO100201700012C come up for recompete?

SCOUT tracks a period-of-performance end of Sep 27, 2027. Actual solicitation timing can shift with extensions, bridges, or consolidations.

Seen enough? Run one full capture cycle on HHSO100201700012C — $90 for 90 days.

This page stays free. Pilot is the live layer: displacement scoring, recompete pipeline, Daily Brief, and SCOUT MCP for 90 days. If you already live in Claude or ChatGPT and only need live search, start MCP Explorer at $29/mo.

Start Pilot — $90

$1/day · one payment · no subscription

Use SCOUT in your AI client — $29/mo

Classify + search inside Claude, ChatGPT, Cursor

Compare plans

Data: Showing contracts ≥ $100K from federal procurement records (FPDS-NG, SAM.gov, and related repositories), normalized by PrimeRFP SCOUT. Each row keyed by Award ID (PIID); task orders appear as independent rows.

Data as of Aug 20, 2026 · refreshed monthlyLatest procurement action Jun 27, 2024